Advanced

Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response

Carlsson, T; Reichard, O; Norkrans, G; Bläckberg, Jonas LU ; Sangfelt, P; Wallmark, E and Weiland, O (2005) In Journal of Viral Hepatitis 12(5). p.473-480
Abstract
To optimize treatment of chronic hepatitis C early identification of patients who will not achieve a sustained virological response (SVR) is desirable. We investigated hepatitis C virus (HCV) RNA kinetics at day 1 (in 15 patients; genotypes 1 and non-1, 9 and 6 respectively) at weeks 1, 4 and 12 (in 53 patients; genotypes 1 and non-1, 19 and 34, respectively) during treatment with pegylated interferon alpha-2a and ribavirin. Patients with SVR had a significantly more pronounced mean log(10) decline from baseline in HCV RNA levels at weeks 1 and 4 compared with patients who failed to achieve SVR (1.99 vs 0.85 at week 1, P = 0.0003 and 2.89 vs 1.72 at week 4, P = 0.0159), whereas no difference was noted after day 1. For patients with a... (More)
To optimize treatment of chronic hepatitis C early identification of patients who will not achieve a sustained virological response (SVR) is desirable. We investigated hepatitis C virus (HCV) RNA kinetics at day 1 (in 15 patients; genotypes 1 and non-1, 9 and 6 respectively) at weeks 1, 4 and 12 (in 53 patients; genotypes 1 and non-1, 19 and 34, respectively) during treatment with pegylated interferon alpha-2a and ribavirin. Patients with SVR had a significantly more pronounced mean log(10) decline from baseline in HCV RNA levels at weeks 1 and 4 compared with patients who failed to achieve SVR (1.99 vs 0.85 at week 1, P = 0.0003 and 2.89 vs 1.72 at week 4, P = 0.0159), whereas no difference was noted after day 1. For patients with a 2-log(10) decrease in HCV RNA levels at day 7, the positive predictive value (PPV) for a SVR was 92%, whereas week 12 was the best time point for predicting a later nonresponse [negative predictive value (NPV) 92%] in patients failing to achieve a 2-log(10) drop. For patients with genotype non-1 and a 2-log(10) decrease in HCV RNA levels the PPV for a SVR was 89% week 1, and 79% weeks 4 and 12. The corresponding NPV for patients with genotype non-1 were 43, 40 and 100% respectively. During treatment with pegylated interferon alpha-2a plus ribavirin the HCV RNA decline at week 1 was an accurate predictor of SVR in patients who had achieved a 2-log(10) drop in HCV RNA levels, whereas the lack of such decline week 12 was an accurate marker of a nonresponse. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
ribavirin, sustained virological response, hepatitis C virus RNA, pegylated interferon alpha-2a
in
Journal of Viral Hepatitis
volume
12
issue
5
pages
473 - 480
publisher
Wiley-Blackwell
external identifiers
  • wos:000231223400004
  • pmid:16108761
  • scopus:24044531933
ISSN
1365-2893
DOI
10.1111/j.1365-2893.2005.00621.x
language
English
LU publication?
yes
id
2f984a93-f767-42a4-817c-377f08cab2d8 (old id 227452)
date added to LUP
2007-08-14 13:02:27
date last changed
2017-01-01 04:48:00
@article{2f984a93-f767-42a4-817c-377f08cab2d8,
  abstract     = {To optimize treatment of chronic hepatitis C early identification of patients who will not achieve a sustained virological response (SVR) is desirable. We investigated hepatitis C virus (HCV) RNA kinetics at day 1 (in 15 patients; genotypes 1 and non-1, 9 and 6 respectively) at weeks 1, 4 and 12 (in 53 patients; genotypes 1 and non-1, 19 and 34, respectively) during treatment with pegylated interferon alpha-2a and ribavirin. Patients with SVR had a significantly more pronounced mean log(10) decline from baseline in HCV RNA levels at weeks 1 and 4 compared with patients who failed to achieve SVR (1.99 vs 0.85 at week 1, P = 0.0003 and 2.89 vs 1.72 at week 4, P = 0.0159), whereas no difference was noted after day 1. For patients with a 2-log(10) decrease in HCV RNA levels at day 7, the positive predictive value (PPV) for a SVR was 92%, whereas week 12 was the best time point for predicting a later nonresponse [negative predictive value (NPV) 92%] in patients failing to achieve a 2-log(10) drop. For patients with genotype non-1 and a 2-log(10) decrease in HCV RNA levels the PPV for a SVR was 89% week 1, and 79% weeks 4 and 12. The corresponding NPV for patients with genotype non-1 were 43, 40 and 100% respectively. During treatment with pegylated interferon alpha-2a plus ribavirin the HCV RNA decline at week 1 was an accurate predictor of SVR in patients who had achieved a 2-log(10) drop in HCV RNA levels, whereas the lack of such decline week 12 was an accurate marker of a nonresponse.},
  author       = {Carlsson, T and Reichard, O and Norkrans, G and Bläckberg, Jonas and Sangfelt, P and Wallmark, E and Weiland, O},
  issn         = {1365-2893},
  keyword      = {ribavirin,sustained virological response,hepatitis C virus RNA,pegylated interferon alpha-2a},
  language     = {eng},
  number       = {5},
  pages        = {473--480},
  publisher    = {Wiley-Blackwell},
  series       = {Journal of Viral Hepatitis},
  title        = {Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response},
  url          = {http://dx.doi.org/10.1111/j.1365-2893.2005.00621.x},
  volume       = {12},
  year         = {2005},
}